Explore
Validate
Learn10986-1-AP
antibody from Proteintech Group
Targeting: NDUFA13
B16.6, CDA016, CGI-39, GRIM-19, GRIM19
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10986-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10986-1-AP, RRID:AB_2150609
- Product name
- GRIM19 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated GRIM19 antibody (Cat. #10986-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, IP, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references GRIM-19 inhibits proliferation and induces apoptosis in a p53-dependent manner in colorectal cancer cells through the SIRT7/PCAF/MDM2 axis.
GRIM-19 deficiency promotes clear cell renal cell carcinoma progression and is associated with high TNM stage and Fuhrman grade.
Clinical and molecular findings in a family expressing a novel heterozygous variant of the G elongation factor mitochondrial 1 gene.
Nonviral Delivery of GRIM-19 Gene Inhibits Tumor Growth with Reduced Local and Systemic Complications.
Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Atrazine promotes RM1 prostate cancer cell proliferation by activating STAT3 signaling.
Wang D, Wei X, Chen X, Wang Q, Zhang J, Kalvakolanu DV, Guo B, Zhang L
Experimental cell research 2021 Oct 1;407(1):112799
Experimental cell research 2021 Oct 1;407(1):112799
GRIM-19 deficiency promotes clear cell renal cell carcinoma progression and is associated with high TNM stage and Fuhrman grade.
Yan N, Feng X, Jiang S, Sun W, Sun MZ, Liu S
Oncology letters 2020 Jun;19(6):4115-4121
Oncology letters 2020 Jun;19(6):4115-4121
Clinical and molecular findings in a family expressing a novel heterozygous variant of the G elongation factor mitochondrial 1 gene.
Su C, Wang F
Experimental and therapeutic medicine 2020 Dec;20(6):173
Experimental and therapeutic medicine 2020 Dec;20(6):173
Nonviral Delivery of GRIM-19 Gene Inhibits Tumor Growth with Reduced Local and Systemic Complications.
Xu Y, Wang X, Guo B, Wang D, Kalvakolanu DV, Chen X, Tang J, Zhang L, Yang Q
Human gene therapy 2019 Nov;30(11):1419-1430
Human gene therapy 2019 Nov;30(11):1419-1430
Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F, Yan CY, Zhou S, Hui PY, Du YH, Zheng L, Yu J, Hu XJ, Zhang ZG
Cancer chemotherapy and pharmacology 2018 Oct;82(4):593-605
Cancer chemotherapy and pharmacology 2018 Oct;82(4):593-605
Atrazine promotes RM1 prostate cancer cell proliferation by activating STAT3 signaling.
Hu K, Tian Y, Du Y, Huang L, Chen J, Li N, Liu W, Liang Z, Zhao L
International journal of oncology 2016 May;48(5):2166-74
International journal of oncology 2016 May;48(5):2166-74
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human placenta tissue were subjected to SDS PAGE followed by western blot with 10986-1-AP(GRIM19 antibody) at dilution of 1:800
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The GRIM19 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human GRIM19. This antibody recognizes human,mouse,rat antigen. The GRIM19 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
